Study of Palbociclib Combined With Chemotherapy in Pediatric Patients With Recurrent/Refractory Solid Tumors
Phase 1/2 Study to Evaluate Palbociclib (Ibrance®) in Combination With Irinotecan and Temozolomide or in Combination With Topotecan and Cyclophosphamide in Pediatric Patients With Recurrent or Refractory Solid Tumors
Category & Conditions: Cancer
Medicine: Ibrance (palbociclib)
ClinicalTrials.gov Identifier (NCT): NCT03709680
Protocol ID: A5481092
Open Plain Language Summary Result:
Click here